Epirubicin and long-term heart failure risk in breast cancer survivors

Eur J Heart Fail. 2018 Oct;20(10):1454-1456. doi: 10.1002/ejhf.1215. Epub 2018 Jul 4.

Authors

Syed S Mahmood¹, Ravi B Patel², Javed Butler³, Muthiah Vaduganathan⁴

Affiliations

¹ Division of Cardiology, New York Presbyterian Hospital-Weill Cornell Medical Center, New York, NY, USA.
² Division of Cardiology, Bluhm Cardiovascular Institute at Northwestern Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
³ Department of Medicine, University of Mississippi, Jackson, MS, USA.
⁴ Brigham and Women's Hospital Heart & Vascular Center and Harvard Medical School, Boston, MA, USA.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Extramural
Comment

MeSH terms

Antibiotics, Antineoplastic
Breast Neoplasms
Cancer Survivors
Epirubicin*
Female
Heart Failure*
Humans
Incidence

Substances

Antibiotics, Antineoplastic
Epirubicin

Grants and funding